Abstract:Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). The cis P‐tau but not trans P‐tau is resistant to protein dephosphorylation and degradation and also prone to protein aggregation and serves as an early driver of multiple neurodegenerative disease including Alzheimer disease (AD), traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis P‐tau antibody is the only clinical‐stage therapeutic for AD that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. In this article, we review the role of cis P‐tau in neurodegenerative diseases and its regulation as a potential drug target. A schematic drawing of cis and trans pT231P of tau protein. Cis but not trans P‐tau is induced by multiple stresses and contributes to neurodegenerative diseases. Cis P‐tau is converted into trans P‐tau by Pin1. Conventional tauopathies are a group of disease characterized by tau inclusions in the brains, including Alzheimer's disease (AD), Pick's disease (PiD), progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and certain types of frontotemporal dementia (FTD), among which AD is the most prevalent. Extensive post‐translational modifications, especially hyperphosphorylation, and abnormal aggregation of tau protein underlie tauopathy. Cis–trans isomerization of protein plays an important role in protein folding, function, and degradation, which is regulated by peptidyl‐proline isomerases (PPIases). Peptidyl‐prolyl cis–trans isomerase NIMA‐interacting 1 (Pin1), the only PPIase found to isomerize Pro following phosphorylated Ser or Thr residues, alters phosphorylated tau protein conformation at pT231‐P motif. The cis P‐tau but not trans P‐tau serves as an early driver of multiple neurodegenerative disease, encompassing AD, traumatic brain injury (TBI), chronic traumatic encephalopathy (CTE), and vascular contributions to cognitive impairment and dementia (VCID). Cis but not trans P‐tau is resistant to protein dephosphorylation and degradation, and also prone to protein aggregation. Cis P‐tau loses its ability to stabilize microtubule, causing and spreading tauopathy mainly in axons, a pathological process called cistauosis. The conformation‐specific monoclonal antibody that targets only the cis P‐tau serves as a very early diagnosis method and a potential treatment of not only conventional tauopathies but also nonconventional tauopathies such as VCID, with clinical trials ongoing. Notably, cis P‐tau antibody is the only clinical‐stage Alzheimer's therapeutic that has shown the efficacy in animal models of not only AD but also TBI and stroke, which are very early stages of dementia. Here we review the identification and pathological consequences of cis pt231‐tau, the role of its regulator Pin1, as well as the clinical implication of cis pt231‐tau conformation‐specific antibody in conventional and nonconventional tauopathies.

Regulation of tau by peptidyl-prolyl isomerases

Function and regulation of cis P‐tau in the pathogenesis and treatment of conventional and nonconventional tauopathies

Developmental Regulation of Tau Phosphorylation, Tau Kinases, and Tau Phosphatases

Tau Post-translational Modifications: Dynamic Transformers of Tau Function, Degradation, and Aggregation

Tau Modulates mRNA Transcription, Alternative Polyadenylation Profiles of hnRNPs, Chromatin Remodeling and Spliceosome Complexes

Structural Insights into the Role of the Proline Rich Region in Tau Function

G-protein coupled receptors regulates Tauopathy in neurodegeneration

Protein tau phosphorylation in the proline rich region and its implication in the progression of Alzheimer's disease

A Unique Tau Conformation Generated by an Acetylation-Mimic Substitution Modulates P301S-dependent Tau Pathology and Hyperphosphorylation.

Regulatory B Subunits of Protein Phosphatase 2A Are Involved in Site-specific Regulation of Tau Protein Phosphorylation

Post-Translational Modifications in Tau and Their Roles in Alzheimer's Pathology

Phosphorylation of tau at a single residue inhibits binding to the E3 ubiquitin ligase, CHIP

Tau in physiology and pathology

Regulation of neuronal microtubule dynamics by tau: Implications for tauopathies

Identification of a Reciprocal Negative Feedback Loop Between Tau-Modifying Proteins MARK2 Kinase and CBP Acetyltransferase.

Peptidyl-Prolyl Cis/Trans Isomerase Pin1 and Alzheimer’s Disease

PP2A Subunit PPP2R2C is Downregulated in the Brains of Alzheimer's Transgenic Mice.

SUMO1 modification of 0N4R-tau is regulated by PIASx, SENP1, SENP2, and TRIM11

Phosphorylation of Trans‐active Response DNA‐binding Protein‐of 43 Kda Promotes Its Cytoplasmic Aggregation and Modulates Its Function in Tau Mrna Stability and Exon 10 Alternative Splicing

An acetylation–phosphorylation switch that regulates tau aggregation propensity and function

Abnormal protein post-translational modifications induces aggregation and abnormal deposition of protein, mediating neurodegenerative diseases